ArticleFrontiers in oncology2023
The associated risk of
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Global prevalence and correlation of intestinal parasitic infections in patients with colorectal cancer: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Global prevalence of intestinal parasites in cancer patients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Prevalence and subtype distribution of Blastocystis infections among community participants in Thailand: a systematic review and meta-analysis.Parasite (Paris, France) · 2025Pooled it
- Microbiota composition effect on immunotherapy outcomes in colorectal cancer patients: A systematic review.PloS one · 2024Pooled it
- Prevalence of Blastocystis infection in patients with colorectal cancer in Taiwan.BMC infectious diseases · 2025Article
- Assessment of immunological and hematological parameters in Blastocystis species-infected chronic leukemic patients.Gut pathogens · 2025Article
- The Role ofPathogens (Basel, Switzerland) · 2025Review
- Multi-marker comparative analysis of 18S, ITS1, and ITS2 primers for human gut mycobiome profiling.Frontiers in bioinformatics · 2025Article
- Cytological identification ofFrontiers in medicine · 2025Article
- An Update onMicroorganisms · 2024Review
- Clinical Significance and Subtype Distribution ofIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We used a case-control design; cancer patients and cancer-free (CF) participants. The cancer group was further sub-group into CRC group and cancers outside the gastrointestinal tract (COGT) group. Macroscopic and microscopic examinations were performed to identify intestinal parasites in participants' stool samples. Molecular and phylogenetic analyses were conducted to identify and subtype Results: 104 stool samples were collected and matched between CF (n=52) and cancer patients (n=52); CRC (n=15) and COGT (n=37). As anticipated, Conclusion: Cancer patients have a higher risk of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.